CG Oncology Announces $105 Million Oversubscribed Crossover …

Aug 2, 2023 · “Our lead asset, cretostimogene grenadenorepvec, continues to make significant clinical progress in bladder cancer in both monotherapy and in combination studies and we are …

CouponFollow Extension

$105
OFF

CG Oncology Announces $105 Million Oversubscribed Crossover …

4 weeks from now

Aug 2, 2023 · “Our lead asset, cretostimogene grenadenorepvec, continues to make significant clinical progress in bladder cancer in both monotherapy and in combination studies and we are …

cgoncology.com

$105
OFF

CG Raises $105M Crossover Round To Fund Phase 3 Cancer Trial

4 weeks from now

Aug 2, 2023 · Once ubiquitous, the pre-IPO rounds have dried up in the biotech bear market—but CG’s fully enrolled phase 3 bladder cancer clinical trial has persuaded investors to dig out their …

fiercebiotech.com

$105
OFF

CG Oncology Announces $105 Million Oversubscribed Crossover …

4 weeks from now

Aug 2, 2023 · “Our lead asset, cretostimogene grenadenorepvec, continues to make significant clinical progress in bladder cancer in both monotherapy and in combination studies and we are …

businesswire.com

$105
OFF

CG Oncology Announces $105 Million Oversubscribed Crossover …

4 weeks from now

Aug 2, 2023 · CG Oncology, Inc. announced the close of an oversubscribed $105 million crossover financing round, co-led by new investors Foresite Capital and TCGX, with …

biospace.com

$105
OFF

News Articles About CG Oncology

4 weeks from now

Jan 3, 2024 · Select News articles about CG Oncology; we are focused on developing bladder saving therapeutics for patients with bladder cancer. ... reeling in $105M to fund phase 3 …

cgoncology.com

$105
OFF

Aug. 2 Quick Takes: CG Oncology Raises $105M Crossover Round

4 weeks from now

Aug 2, 2023 · With a Phase III study of its lead oncolytic immunotherapy cretostimogene grenadenorepvec fully enrolled, CG Oncology Inc. has raised $105 million in a series C round …

biocentury.com

$105
OFF

CG Oncology Reels In $105M Crossover For Potential Late 2024 …

4 weeks from now

Aug 2, 2023 · CG Oncology, out to treat bladder cancer patients left behind by the shortage of Merck’s standard BCG therapy or didn't benefit from it in the first place, has reeled in ...

endpts.com

$105
OFF

CG Oncology Announces $105 Million Oversubscribed …

4 weeks from now

“Our lead asset, cretostimogene grenadenorepvec, continues to make significant clinical progress in bladder cancer in both monotherapy and in combination studies and we are encouraged to …

cgoncology.com

$120
OFF

CG Oncology Raises $120 Million In Oversubscribed Series E …

4 weeks from now

Nov 15, 2022 · “Our continued clinical progress in bladder cancer is a testament to our lead candidate CG0070 in both monotherapy and combination therapy studies, setting the stage to …

cgoncology.com

2%
OFF

CG Sets New Bar In Bladder Cancer, Months After Huge IPO - Fierce …

4 weeks from now

May 3, 2024 · The oncolytic-virus-based therapeutic company reported Friday that cretostimogene elicited a 75.2% complete response rate in a late-stage trial among 105 …

fiercebiotech.com

$380
OFF

Bladder Cancer Biotech CG Oncology Raises $380 Million In IPO

4 weeks from now

Jan 25, 2024 · CG Oncology, a biotech focused on bladder cancer, raised $380 million in its IPO, pricing 20 million shares at $19. Why it matters This is a lustrous green light for the broader …

axios.com

FAQs about CG Oncology Announces $105 Million Oversubscribed Crossover … Coupon?

Is CG oncology a potential therapeutic for bladder-cancer patients?

The Irvine, Calif.-based biopharmaceutical company is developing a potential therapeutic for bladder-cancer patients who are unresponsive to immunotherapy Bacillus Calmette-Guerin treatment. CG Oncology did not say how many shares it planned to offer or give an estimated price range. ...

How do you rule out bladder cancer?

Urinalysis: Checking for blood in the urine is one approach to check for bladder cancer ( hematuria). This may be done during a urinalysis, which is a quick test to see if there's any blood or other substances in a urine sample. This test is occasionally performed as part of a routine physical examination. ...

When will CG oncology start a bladder cancer study?

The company said in the filing that it expects to begin this study in the second half of 2024. CG Oncology’s main asset is cretostimogene, an oncolytic virus in late-stage development as a treatment for advanced bladder cancer. The IPO filing follows the report of interim efficacy data showing a 75% complete response rate. ...

Does cg0070 work in patients with bladder cancer unresponsive to BCG?

“In advanced clinical studies CG0070 has continued to demonstrate potentially transformational results in patients with bladder cancer unresponsive to BCG, a difficult-to-treat patient population,” said Brian Liu, M.D., Principal, Longitude Capital. ...

Is CG a good treatment for Urologic Oncology?

During the annual meeting of the Society of Urologic Oncology in November, CG reported interim efficacy data showing a complete response rate of 75.7%, or 50 of the 66 evaluable patients. The therapy was generally well tolerated with adverse effects classified as Grade 1 or 2. ...

Can cretostimogene be used to treat high-risk bladder cancer?

CG has two Phase 3 tests underway. The more advanced study is evaluating cretostimogene in patients whose high-risk bladder cancer has not responded to BCG therapy. The main goal of this open-label clinical trial is to assess a complete response to the therapy. ...